Novo Holdings was already one of the world’s biggest investors in new biopharma companies, but its reach and influence has grown over the last 12 months or so thanks to windfalls not just from the success of Novo Nordisk, but also its own run of hit investments and sales of biotech start-ups.
Wegovy And M&A Deals Help Novo Holdings Expand Biotech Investments
Flush with cash, the controlling stakeholder of Novo Nordisk’s life sciences investment arm is increasing its financing of other biopharma innovators.
